The drug’s efficacy “looks to be highly competitive” and potentially better than rival pills from Novo and Lilly, BMO Capital ...
March 16 () - Structure Therapeutics said its oral obesity drug aleniglipron delivered up to 16.3% weight loss, when ...
Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...
Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong ...
Clinical Trials Arena on MSN
Structure’s obesity pill prompts 16.3% weight loss in Phase II
Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare ...
Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results